Cargando…
Predicting the efficacy of COVID-19 convalescent plasma donor units with the Lumit Dx anti-receptor binding domain assay
BACKGROUND: The novel coronavirus SARS-CoV2 that causes COVID-19 has resulted in the death of more than 2.5 million people, but no cure exists. Although passive immunization with COVID-19 convalescent plasma (CCP) provides a safe and viable therapeutic option, the selection of optimal units for ther...
Autores principales: | Janaka, Sanath Kumar, Clark, Natasha M., Evans, David T., Mou, Huihui, Farzan, Michael, Connor, Joseph P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312954/ https://www.ncbi.nlm.nih.gov/pubmed/34310603 http://dx.doi.org/10.1371/journal.pone.0253551 |
Ejemplares similares
-
Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection
por: Clark, Natasha M., et al.
Publicado: (2022) -
Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection.
por: Clark, Natasha M, et al.
Publicado: (2021) -
Appropriate selection of convalescent plasma donors for COVID-19
por: Tedder, Richard S, et al.
Publicado: (2021) -
COVID19 antibody detection using lateral flow assay tests in a cohort of convalescent plasma donors
por: Ragnesola, Brett, et al.
Publicado: (2020) -
Recruitment Strategy for Potential COVID-19 Convalescent Plasma Donors
por: Andersen, Kylie J., et al.
Publicado: (2020)